^
Association details:
| Biomarker: | HER-2 positive + HER-2 amplification |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1554P - Clinical Impact of ERBB2 copy number and tumor mutation burden (TMB) in patients with HER2- positive advanced gastric cancer treated by nivolumab (N-mab) plus trastuzumab (T-mab) and standard chemotherapy
Published date:
10/16/2023
Excerpt:
We conducted a clinical trial evaluating safety and efficacy of T-mab plus N-mab with S-1/Capecitabine plus oxaliplatin (UMIN000034222). The aim of this study was to investigate the clinical significance of ERBB2 amplification (amp.) and TMB-H for this new combination therapy....Eleven patients with ERBB2 copy number ≥ 50 or TMB-H showed significantly longer PFS (mPFS: 20.8 vs 5.8 months, HR = 0.28 [95%CI 0.09-0.88], p = 0.021) and OS (mOS: not reached vs 15.0 months, HR = 0.10 [95%CI 0.01-0.78], p = 0.007)...High ERBB2 copy number and TMB-H may be a candidate biomarker for this new combination therapy including T-mab and N-mab in patients with HER2-positive advanced gastric cancer.
Secondary therapy:
capecitabine + oxaliplatin; oxaliplatin + gimeracil/oteracil/tegafur
